aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
© aVenture Investment Company, 2025. All rights reserved.
44 Tehama St, San Francisco, CA 94105
Privacy Policy
aVenture Investment Company ("aVenture") is an independent venture capital research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals.
While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision.
aVenture does not offer investment advisory services and is not registered as an investment adviser. The data provided by aVenture does not constitute recommendations or advice, whether by methodology or a statement written by a staff member of aVenture.
Links to external websites do not imply endorsement or affiliation with aVenture. References or links to providers offering the ability to invest in a primary or secondary transaction in a company are for convenience purposes only. They are not solicitations or offers to buy or sell an investment. Remember that past performance does not guarantee future results, and venture capital and private assets should be a contributory part of a diversified portfolio.
Founded in 2006, ImmunArray is a molecular diagnostics company dedicated to improving the accuracy of autoimmune disease diagnosis, with a core mission to enhance patient care through innovative testing solutions. The company's flagship product is a proprietary test designed to rule out lupus in blood samples, addressing the challenge of misdiagnosis and inappropriate treatment that often accompanies this complex disease. ImmunArray's focus is on providing reliable diagnostic tools to healthcare providers, thereby improving patient outcomes in the autoimmune disease market.
Notable figures associated with ImmunArray include key investors and advisors from the medical and biotech industries, though specific names are not publicly highlighted. The company has achieved significant milestones, including the successful introduction of its lupus diagnostic test, which has been recognized for its potential to transform lupus diagnosis. ImmunArray's impact lies in its contribution to reducing diagnostic errors and enhancing the precision of autoimmune disease management, positioning it as a critical player in the molecular diagnostics landscape.
Operating Status
Closed
Ownership Type(s)
Private
Main Product(s)
Diagnostics
Technology
Biotech
Tags
Healthtech
Model Types
Software
Revenue Type(s)
Transactional
Customer Type(s)
Enterprise
Geographic Exposure
United States
When was ImmunArray founded?
ImmunArray was founded in 2006.
Where is ImmunArray’s headquarters located?
ImmunArray’s headquarters is located in Richmond, US.
When was ImmunArray’s last funding round?
ImmunArray’s most recent funding round was for $10M (USD) in July 2016.
How many employees does ImmunArray have?
ImmunArray has 75 employees as of Feb 4, 2024.
How much has ImmunArray raised to-date?
As of July 05, 2023, ImmunArray has raised a total of $10M (USD) since Jul 12, 2016.
Add Comparison
Total Raised to Date
$10M
USD
Last Update Jul 12, 2016
Last Deal Details
$10M
USD
Jul 12, 2016
Series Unknown
Total Employees Over Time
75
As of Feb 2024
ImmunArray Address
737 N 5th St
Suite 304
Richmond,
23219
United States
Source(s): This page includes data and analysis provided by the company, OpenAI, and our research analysts